Early Alzheimer’s Guidance: FDA Puts Forth New Endpoint Possibilities for Stage 3 Disease

 
• By Sarah Karlin-Smith
  
PET scan images of the human brain
New endpoint flexibility in FDA guidance could make for shorter clinical trials in Stage 3 Alzheimer's disease • Source: Shutterstock

More from US FDA

More from Agency Leadership